|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCAPD2 |
Gene summary for NCAPD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCAPD2 | Gene ID | 9918 |
| Gene name | non-SMC condensin I complex subunit D2 | |
| Gene Alias | CAP-D2 | |
| Cytomap | 12p13.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B3KMS0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9918 | NCAPD2 | P48T-E | Human | Esophagus | ESCC | 1.95e-14 | 1.75e-01 | 0.0959 |
| 9918 | NCAPD2 | P49T-E | Human | Esophagus | ESCC | 7.97e-03 | 8.97e-01 | 0.1768 |
| 9918 | NCAPD2 | P52T-E | Human | Esophagus | ESCC | 7.36e-14 | 4.34e-01 | 0.1555 |
| 9918 | NCAPD2 | P54T-E | Human | Esophagus | ESCC | 1.41e-05 | 1.87e-01 | 0.0975 |
| 9918 | NCAPD2 | P56T-E | Human | Esophagus | ESCC | 3.00e-05 | 7.57e-01 | 0.1613 |
| 9918 | NCAPD2 | P57T-E | Human | Esophagus | ESCC | 4.40e-02 | 7.21e-02 | 0.0926 |
| 9918 | NCAPD2 | P61T-E | Human | Esophagus | ESCC | 9.54e-04 | 2.17e-01 | 0.099 |
| 9918 | NCAPD2 | P62T-E | Human | Esophagus | ESCC | 2.04e-07 | 3.16e-01 | 0.1302 |
| 9918 | NCAPD2 | P65T-E | Human | Esophagus | ESCC | 1.81e-02 | 7.74e-02 | 0.0978 |
| 9918 | NCAPD2 | P74T-E | Human | Esophagus | ESCC | 1.37e-11 | 6.85e-01 | 0.1479 |
| 9918 | NCAPD2 | P76T-E | Human | Esophagus | ESCC | 1.81e-10 | 3.54e-01 | 0.1207 |
| 9918 | NCAPD2 | P79T-E | Human | Esophagus | ESCC | 7.66e-12 | 4.20e-01 | 0.1154 |
| 9918 | NCAPD2 | P80T-E | Human | Esophagus | ESCC | 3.33e-06 | 1.43e-01 | 0.155 |
| 9918 | NCAPD2 | P83T-E | Human | Esophagus | ESCC | 1.55e-21 | 9.12e-01 | 0.1738 |
| 9918 | NCAPD2 | P89T-E | Human | Esophagus | ESCC | 2.77e-09 | 8.96e-01 | 0.1752 |
| 9918 | NCAPD2 | P91T-E | Human | Esophagus | ESCC | 5.33e-11 | 1.36e+00 | 0.1828 |
| 9918 | NCAPD2 | P107T-E | Human | Esophagus | ESCC | 1.64e-16 | 6.74e-01 | 0.171 |
| 9918 | NCAPD2 | P127T-E | Human | Esophagus | ESCC | 6.71e-04 | 9.53e-02 | 0.0826 |
| 9918 | NCAPD2 | P128T-E | Human | Esophagus | ESCC | 1.56e-07 | 2.48e-01 | 0.1241 |
| 9918 | NCAPD2 | P130T-E | Human | Esophagus | ESCC | 5.04e-34 | 1.04e+00 | 0.1676 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
| GO:01400141 | Colorectum | MSS | mitotic nuclear division | 70/3467 | 287/18723 | 7.48e-03 | 4.72e-02 | 70 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:00070761 | Esophagus | ESCC | mitotic chromosome condensation | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
| GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
| GO:0000070 | Liver | HCC | mitotic sister chromatid segregation | 110/7958 | 168/18723 | 1.42e-09 | 4.25e-08 | 110 |
| GO:00008191 | Liver | HCC | sister chromatid segregation | 128/7958 | 202/18723 | 1.59e-09 | 4.73e-08 | 128 |
| GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
| GO:0098813 | Liver | HCC | nuclear chromosome segregation | 157/7958 | 281/18723 | 3.82e-06 | 4.95e-05 | 157 |
| GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
| GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
| GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
| GO:00000702 | Oral cavity | OSCC | mitotic sister chromatid segregation | 118/7305 | 168/18723 | 1.89e-16 | 1.48e-14 | 118 |
| GO:00008193 | Oral cavity | OSCC | sister chromatid segregation | 135/7305 | 202/18723 | 8.88e-16 | 6.52e-14 | 135 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCAPD2 | SNV | Missense_Mutation | novel | c.1932N>C | p.Met644Ile | p.M644I | Q15021 | protein_coding | deleterious(0.01) | benign(0.184) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| NCAPD2 | SNV | Missense_Mutation | rs369341180 | c.1169N>A | p.Arg390Gln | p.R390Q | Q15021 | protein_coding | deleterious(0.04) | probably_damaging(0.961) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NCAPD2 | SNV | Missense_Mutation | c.3245N>C | p.Leu1082Pro | p.L1082P | Q15021 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NCAPD2 | insertion | Frame_Shift_Ins | novel | c.3066_3067insATGTGCAA | p.Asn1023MetfsTer27 | p.N1023Mfs*27 | Q15021 | protein_coding | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD | ||
| NCAPD2 | insertion | In_Frame_Ins | novel | c.2420_2421insAAGCTTCCTGAAGGT | p.Gln807_Asp808insSerPheLeuLysVal | p.Q807_D808insSFLKV | Q15021 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| NCAPD2 | SNV | Missense_Mutation | novel | c.2233N>G | p.Lys745Glu | p.K745E | Q15021 | protein_coding | deleterious(0.02) | benign(0.057) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NCAPD2 | SNV | Missense_Mutation | novel | c.2597N>T | p.Pro866Leu | p.P866L | Q15021 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NCAPD2 | SNV | Missense_Mutation | rs771553945 | c.3644N>A | p.Arg1215His | p.R1215H | Q15021 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NCAPD2 | SNV | Missense_Mutation | novel | c.2858G>A | p.Arg953Gln | p.R953Q | Q15021 | protein_coding | tolerated(0.06) | possibly_damaging(0.487) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| NCAPD2 | SNV | Missense_Mutation | novel | c.3055N>G | p.Leu1019Val | p.L1019V | Q15021 | protein_coding | tolerated(0.78) | benign(0.04) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |